{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:32Z","timestamp":1787003492740,"version":"build-2736575974"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41590-026-02478-7","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:08:04Z","timestamp":1774433284000},"page":"1224-1236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5631-8101","authenticated-orcid":false,"given":"Lara","family":"Kelchtermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuong Thi","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanshika","family":"Malviya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien","family":"De Keyzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-684X","authenticated-orcid":false,"given":"Elias","family":"Broeckhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-3388","authenticated-orcid":false,"given":"Susan","family":"Schlenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-5393","authenticated-orcid":false,"given":"Yeranddy A.","family":"Alpizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-9166","authenticated-orcid":false,"given":"Kai","family":"Dallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2478_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1179\/2047773214Y.0000000169","volume":"109","author":"SM Bartsch","year":"2015","unstructured":"Bartsch, S. M., Gorham, K. & Lee, B. Y. The cost of an Ebola case. Pathog. Glob. Health 109, 4\u20139 (2015).","journal-title":"Pathog. Glob. Health"},{"key":"2478_CR2","unstructured":"World Health Organization. Sudan virus disease\u2014Uganda https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON555 (2025)."},{"key":"2478_CR3","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1086\/520545","volume":"196","author":"DG Bausch","year":"2007","unstructured":"Bausch, D. G. et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 196, S142\u2013S147 (2007).","journal-title":"J. Infect. Dis."},{"key":"2478_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-010982","volume":"7","author":"SK Ibrahim","year":"2022","unstructured":"Ibrahim, S. K., Ndwandwe, D. E., Thomas, K., Sigfrid, L. & Norton, A. Sudan virus disease outbreak in Uganda: urgent research gaps. BMJ Glob. Health 7, e010982 (2022).","journal-title":"BMJ Glob. Health"},{"key":"2478_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02847-1","volume":"21","author":"G Bwire","year":"2023","unstructured":"Bwire, G. et al. Sudan Ebola virus (SUDV) outbreak in Uganda, 2022: lessons learnt and future priorities for sub-Saharan Africa. BMC Med. 21, 144 (2023).","journal-title":"BMC Med."},{"key":"2478_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jiph.2023.10.020","volume":"17","author":"J Izudi","year":"2024","unstructured":"Izudi, J. & Bajunirwe, F. Case fatality rate for Ebola disease, 1976\u20132022: a meta-analysis of global data. J. Infect. Public Health 17, 25\u201334 (2024).","journal-title":"J. Infect. Public Health"},{"key":"2478_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09391-0","volume":"24","author":"A Komakech","year":"2024","unstructured":"Komakech, A. et al. Sudan virus disease super-spreading, Uganda, 2022. BMC Infect. Dis. 24, 520 (2024).","journal-title":"BMC Infect. Dis."},{"key":"2478_CR8","unstructured":"Africa Centers for Disease Control and Prevention. Guidelines for Enhanced Surveillance of Sudan Virus Disease https:\/\/africacdc.org\/download\/guidelines-for-enhanced-surveillance-of-sudan-virus-disease\/ (2023)."},{"key":"2478_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijid.2023.01.008","volume":"128","author":"P Musoke","year":"2023","unstructured":"Musoke, P. & Bongomin, F. Sudan virus disease outbreak in Uganda in 2022: the case of patient zero. Int. J. Infect. Dis. 128, 318\u2013320 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"2478_CR10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/22221751.2022.2086072","volume":"11","author":"C Woolsey","year":"2022","unstructured":"Woolsey, C. et al. Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques. Emerg. Microbes Infect. 11, 1635\u20131646 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"2478_CR11","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.3390\/v7102867","volume":"7","author":"SM Anthony","year":"2015","unstructured":"Anthony, S. M. & Bradfute, S. B. Filoviruses: one of these things is (not) like the other. Viruses 7, 5172\u20135190 (2015).","journal-title":"Viruses"},{"key":"2478_CR12","unstructured":"World Health Organization. Sudan Virus Disease (SVD) caused by Sudan Virus (SUDV) https:\/\/www.afro.who.int\/health-topics\/ebola-disease\/sudan-virus-disease (2022)."},{"key":"2478_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00685-z","volume":"8","author":"W Cao","year":"2023","unstructured":"Cao, W. et al. The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs. NPJ Vaccines 8, 91 (2023).","journal-title":"NPJ Vaccines"},{"key":"2478_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"key":"2478_CR15","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","volume":"4","author":"A Marzi","year":"2023","unstructured":"Marzi, A. et al. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques. Lancet Microbe 4, e171\u2013e178 (2023).","journal-title":"Lancet Microbe"},{"key":"2478_CR16","doi-asserted-by":"publisher","unstructured":"Honko, A. N. et al. A single-shot ChAd3 vaccine provides protection from intramuscular and aerosol Sudan virus exposure. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.02.07.579118 (2024).","DOI":"10.1101\/2024.02.07.579118"},{"key":"2478_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/infdis\/jiae056","volume":"230","author":"S van Tol","year":"2024","unstructured":"van Tol, S. et al. A bivalent adenovirus-vectored vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus. J. Infect. Dis. 230, 1083\u20131092 (2024).","journal-title":"J. Infect. Dis."},{"key":"2478_CR18","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S2666-5247(20)30198-1","volume":"2","author":"RF Grais","year":"2021","unstructured":"Grais, R. F. et al. Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2\/3 clinical trials. Lancet Microbe 2, e70\u2013e78 (2021).","journal-title":"Lancet Microbe"},{"key":"2478_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","volume":"27","author":"M Meyer","year":"2019","unstructured":"Meyer, M., Malherbe, D. C. & Bukreyev, A. Can Ebola virus vaccines have universal immune correlates of protection? Trends Microbiol. 27, 8\u201316 (2019).","journal-title":"Trends Microbiol."},{"key":"2478_CR20","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1080\/21645515.2020.1741313","volume":"16","author":"DN Wolfe","year":"2020","unstructured":"Wolfe, D. N., Taylor, M. J. & Zarrabian, A. G. Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus. Hum. Vaccin. Immunother. 16, 2855\u20132860 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2478_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41590-024-01787-z","volume":"25","author":"V Fumagalli","year":"2024","unstructured":"Fumagalli, V. et al. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat. Immunol. 25, 633\u2013643 (2024).","journal-title":"Nat. Immunol."},{"key":"2478_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","volume":"601","author":"L Swadling","year":"2022","unstructured":"Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601, 110\u2013117 (2022).","journal-title":"Nature"},{"key":"2478_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","volume":"18","author":"TM Wilkinson","year":"2012","unstructured":"Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274\u2013280 (2012).","journal-title":"Nat. Med."},{"key":"2478_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.168110","volume":"8","author":"C De","year":"2023","unstructured":"De, C. et al. Human T cells efficiently control RSV infection. JCI Insight 8, e168110 (2023).","journal-title":"JCI Insight"},{"key":"2478_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","volume":"10","author":"S Kalimuddin","year":"2025","unstructured":"Kalimuddin, S. et al. Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. Nat. Microbiol. 10, 374\u2013387 (2025).","journal-title":"Nat. Microbiol."},{"key":"2478_CR26","doi-asserted-by":"publisher","first-page":"e02494","DOI":"10.1128\/mBio.02494-19","volume":"11","author":"N Mishra","year":"2020","unstructured":"Mishra, N. et al. A Chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies. mBio 11, e02494\u201302419 (2020).","journal-title":"mBio"},{"key":"2478_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41564-024-01921-5","volume":"10","author":"YA Alpizar","year":"2025","unstructured":"Alpizar, Y. A. & Dallmeier, K. T cell-mediated protection in absence of virus neutralizing antibodies. Nat. Microbiol. 10, 277\u2013278 (2025).","journal-title":"Nat. Microbiol."},{"key":"2478_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00472-24","volume":"93","author":"A Bahl","year":"2025","unstructured":"Bahl, A., Pandey, S., Rakshit, R., Kant, S. & Tripathi, D. Infection-induced trained immunity: a twist in paradigm of innate host defense and generation of immunological memory. Infect. Immun. 93, e0047224 (2025).","journal-title":"Infect. Immun."},{"key":"2478_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00699-7","volume":"8","author":"V Lemmens","year":"2023","unstructured":"Lemmens, V. et al. YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge. NPJ Vaccines 8, 99 (2023).","journal-title":"NPJ Vaccines"},{"key":"2478_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250133","volume":"54","author":"L Sanchez-Felipe","year":"2024","unstructured":"Sanchez-Felipe, L., Alpizar, Y. A., Ma, J., Coelmont, L. & Dallmeier, K. YF17D-based vaccines\u2014standing on the shoulders of a giant. Eur. J. Immunol. 54, e2250133 (2024).","journal-title":"Eur. J. Immunol."},{"key":"2478_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223 (2018).","journal-title":"Nat. Commun."},{"key":"2478_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00652-17","volume":"91","author":"J Duehr","year":"2017","unstructured":"Duehr, J. et al. Novel cross-reactive monoclonal antibodies against ebolavirus glycoproteins show protection in a murine challenge model. J Virol. 91, e00652-17 (2017).","journal-title":"J Virol."},{"key":"2478_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012134","volume":"20","author":"AS Wirchnianski","year":"2024","unstructured":"Wirchnianski, A. S. et al. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies. PLoS Pathog. 20, e1012134 (2024).","journal-title":"PLoS Pathog."},{"key":"2478_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","volume":"590","author":"L Sanchez-Felipe","year":"2021","unstructured":"Sanchez-Felipe, L. et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590, 320\u2013325 (2021).","journal-title":"Nature"},{"key":"2478_CR35","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1080\/22221751.2021.2008772","volume":"10","author":"J Ma","year":"2021","unstructured":"Ma, J. et al. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice. Emerg. Microbes Infect. 10, 2279\u20132290 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"2478_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/v13071388","volume":"13","author":"O Escaffre","year":"2021","unstructured":"Escaffre, O. et al. STAT-1 knockout mice as a model for wild-type Sudan virus (SUDV). Viruses 13, 1388 (2021).","journal-title":"Viruses"},{"key":"2478_CR37","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2006-06-027599","volume":"108","author":"E Kamphuis","year":"2006","unstructured":"Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108, 3253\u20133261 (2006).","journal-title":"Blood"},{"key":"2478_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0008-8749(83)90046-1","volume":"79","author":"A Schattner","year":"1983","unstructured":"Schattner, A., Meshorer, A. & Wallach, D. Involvement of interferon in virus-induced lymphopenia. Cell Immunol. 79, 11\u201325 (1983).","journal-title":"Cell Immunol."},{"key":"2478_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060963","volume":"10","author":"C Carbonnelle","year":"2022","unstructured":"Carbonnelle, C. et al. Natural History of Sudan ebolavirus to support medical countermeasure development. Vaccines (Basel) 10, 963 (2022).","journal-title":"Vaccines (Basel)"},{"key":"2478_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006397","volume":"13","author":"M Iampietro","year":"2017","unstructured":"Iampietro, M. et al. Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLoS Pathog. 13, e1006397 (2017).","journal-title":"PLoS Pathog."},{"key":"2478_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1040093","volume":"13","author":"L Florez-Alvarez","year":"2022","unstructured":"Florez-Alvarez, L. et al. Hemorrhagic fever viruses: pathogenesis, therapeutics, and emerging and re-emerging potential. Front. Microbiol. 13, 1040093 (2022).","journal-title":"Front. Microbiol."},{"key":"2478_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073636","volume":"23","author":"A Buonacera","year":"2022","unstructured":"Buonacera, A., Stancanelli, B., Colaci, M. & Malatino, L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int. J. Mol. Sci. 23, 3636 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2478_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/laban.1298","volume":"46","author":"DL Hickman","year":"2017","unstructured":"Hickman, D. L. Evaluation of the neutrophil:lymphocyte ratio as an indicator of chronic distress in the laboratory mouse. Lab. Anim. (NY) 46, 303\u2013307 (2017).","journal-title":"Lab. Anim. (NY)"},{"key":"2478_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003458","volume":"9","author":"O Vratskikh","year":"2013","unstructured":"Vratskikh, O. et al. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog. 9, e1003458 (2013).","journal-title":"PLoS Pathog."},{"key":"2478_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"2478_CR46","first-page":"141","volume":"411","author":"C Munoz-Fontela","year":"2017","unstructured":"Munoz-Fontela, C. & McElroy, A. K. Ebola virus disease in humans: pathophysiology and immunity. Curr. Top. Microbiol. Immunol. 411, 141\u2013169 (2017).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2478_CR47","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2021.03.009","volume":"54","author":"BM Gunn","year":"2021","unstructured":"Gunn, B. M. et al. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity 54, 815\u2013828 (2021).","journal-title":"Immunity"},{"key":"2478_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1512470","volume":"15","author":"S Vandendriessche","year":"2024","unstructured":"Vandendriessche, S. et al. Complement activation drives the phagocytosis of necrotic cell debris and resolution of liver injury. Front. Immunol. 15, 1512470 (2024).","journal-title":"Front. Immunol."},{"key":"2478_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns, P. & Jonsson, F. Mouse and human FcR effector functions. Immunol. Rev. 268, 25\u201351 (2015).","journal-title":"Immunol. Rev."},{"key":"2478_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005645","volume":"11","author":"E Cimini","year":"2017","unstructured":"Cimini, E. et al. Different features of V\u03b42 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Negl. Trop. Dis. 11, e0005645 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2478_CR51","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2217\/fvl.12.44","volume":"7","author":"NE Martinez","year":"2012","unstructured":"Martinez, N. E. et al. Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis. Future Virol. 7, 593\u2013608 (2012).","journal-title":"Future Virol."},{"key":"2478_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12090992","volume":"12","author":"S Stepkowski","year":"2024","unstructured":"Stepkowski, S. et al. The major role of T regulatory cells in the efficiency of vaccination in general and immunocompromised populations: a review. Vaccines (Basel) 12, 992 (2024).","journal-title":"Vaccines (Basel)"},{"key":"2478_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112402","volume":"42","author":"BM Gunn","year":"2023","unstructured":"Gunn, B. M. et al. Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. Cell Rep. 42, 112402 (2023).","journal-title":"Cell Rep."},{"key":"2478_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6128","volume":"13","author":"M Meyer","year":"2021","unstructured":"Meyer, M. et al. Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Sci. Transl. Med. 13, eabg6128 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2478_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857481","volume":"13","author":"J Mellors","year":"2022","unstructured":"Mellors, J. et al. Complement-mediated neutralisation identified in Ebola virus disease survivor plasma: implications for protection and pathogenesis. Front. Immunol. 13, 857481 (2022).","journal-title":"Front. Immunol."},{"key":"2478_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954936","volume":"13","author":"I Rastogi","year":"2022","unstructured":"Rastogi, I. et al. Role of B cells as antigen presenting cells. Front. Immunol. 13, 954936 (2022).","journal-title":"Front. Immunol."},{"key":"2478_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nri3152","volume":"12","author":"SL Swain","year":"2012","unstructured":"Swain, S. L., McKinstry, K. K. & Strutt, T. M. Expanding roles for CD4+ T cells in immunity to viruses. Nat. Rev. Immunol. 12, 136\u2013148 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2478_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1137-3","volume":"18","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol. 18, 4 (2017).","journal-title":"Genome Biol."},{"key":"2478_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884648","volume":"13","author":"I Terren","year":"2022","unstructured":"Terren, I. et al. Cytokine-induced memory-like NK cells: from the basics to clinical applications. Front. Immunol. 13, 884648 (2022).","journal-title":"Front. Immunol."},{"key":"2478_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature17949","volume":"533","author":"P Ruibal","year":"2016","unstructured":"Ruibal, P. et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 533, 100\u2013104 (2016).","journal-title":"Nature"},{"key":"2478_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/srep43776","volume":"7","author":"A Ludtke","year":"2017","unstructured":"Ludtke, A. et al. Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. Sci. Rep. 7, 43776 (2017).","journal-title":"Sci. Rep."},{"key":"2478_CR62","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1073\/pnas.1209591110","volume":"110","author":"A Marzi","year":"2013","unstructured":"Marzi, A. et al. Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893\u20131898 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2478_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51453-z","volume":"15","author":"A Wiedemann","year":"2024","unstructured":"Wiedemann, A. et al. Long-term cellular immunity of vaccines for Zaire Ebola virus diseases. Nat. Commun. 15, 7666 (2024).","journal-title":"Nat. Commun."},{"key":"2478_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun, L., Su, Y., Jiao, A., Wang, X. & Zhang, B. T cells in health and disease. Signal Transduct. Target. Ther. 8, 235 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2478_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59560-1","volume":"16","author":"KL O\u2019Donnell","year":"2025","unstructured":"O\u2019Donnell, K. L. et al. Single-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease. Nat. Commun. 16, 4199 (2025).","journal-title":"Nat. Commun."},{"key":"2478_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00261-9","volume":"5","author":"R Roozendaal","year":"2020","unstructured":"Roozendaal, R. et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. NPJ Vaccines 5, 112 (2020).","journal-title":"NPJ Vaccines"},{"key":"2478_CR67","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/v4091477","volume":"4","author":"SB Bradfute","year":"2012","unstructured":"Bradfute, S. B., Warfield, K. L. & Bray, M. Mouse models for filovirus infections. Viruses 4, 1477\u20131508 (2012).","journal-title":"Viruses"},{"key":"2478_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.24272\/j.issn.2095-8137.2017.053","volume":"39","author":"V Siragam","year":"2018","unstructured":"Siragam, V., Wong, G. & Qiu, X. G. Animal models for filovirus infections. Zool. Res. 39, 15\u201324 (2018).","journal-title":"Zool. Res."},{"key":"2478_CR69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/vim.2014.0066","volume":"28","author":"J Audet","year":"2015","unstructured":"Audet, J. & Kobinger, G. P. Immune evasion in ebolavirus infections. Viral Immunol. 28, 10\u201318 (2015).","journal-title":"Viral Immunol."},{"key":"2478_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-981-99-0113-5_6","volume":"1407","author":"L Zhang","year":"2023","unstructured":"Zhang, L., Liu, S. & Wang, Y. Pseudotyped viruses for marburgvirus and ebolavirus. Adv. Exp. Med. Biol. 1407, 105\u2013132 (2023).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2478_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/v10060286","volume":"10","author":"JW Froude","year":"2018","unstructured":"Froude, J. W. et al. Post-exposure protection in mice against Sudan virus by a two antibody cocktail. Viruses 10, 286 (2018).","journal-title":"Viruses"},{"key":"2478_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1271236","volume":"14","author":"A Malyshkina","year":"2023","unstructured":"Malyshkina, A., Bruggemann, A., Paschen, A. & Dittmer, U. Cytotoxic CD4+ T cells in chronic viral infections and cancer. Front. Immunol. 14, 1271236 (2023).","journal-title":"Front. Immunol."},{"key":"2478_CR73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2022.05.001","volume":"247","author":"T Preglej","year":"2022","unstructured":"Preglej, T. & Ellmeier, W. CD4+ cytotoxic T cells\u2014phenotype, function and transcriptional networks controlling their differentiation pathways. Immunol. Lett. 247, 27\u201342 (2022).","journal-title":"Immunol. Lett."},{"key":"2478_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1081107","volume":"13","author":"SA Plotkin","year":"2023","unstructured":"Plotkin, S. A. Recent updates on correlates of vaccine-induced protection. Front. Immunol. 13, 1081107 (2023).","journal-title":"Front. Immunol."},{"key":"2478_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105506","volume":"210","author":"W Chiu","year":"2023","unstructured":"Chiu, W. et al. Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery. Antiviral Res. 210, 105506 (2023).","journal-title":"Antiviral Res."},{"key":"2478_CR76","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/nbt1264","volume":"24","author":"MA Mena","year":"2006","unstructured":"Mena, M. A., Treynor, T. P., Mayo, S. L. & Daugherty, P. S. Blue fluorescent proteins with enhanced brightness and photostability from a structurally targeted library. Nat. Biotechnol. 24, 1569\u20131571 (2006).","journal-title":"Nat. Biotechnol."},{"key":"2478_CR77","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"2478_CR78","unstructured":"Boudewijns, R., Dallmeier, K. & Neyts, J. Live-attenuated flaviruses with heterologous antigens. Belgium patent WO\/2019\/068877 (2019)."},{"key":"2478_CR79","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"},{"key":"2478_CR80","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/biomet\/68.1.316","volume":"68","author":"DA Schoenfeld","year":"1981","unstructured":"Schoenfeld, D. A. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 68, 316\u2013319 (1981).","journal-title":"Biometrika"},{"key":"2478_CR81","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2307\/2531021","volume":"39","author":"DA Schoenfeld","year":"1983","unstructured":"Schoenfeld, D. A. Sample-size formula for the proportional-hazards regression model. Biometrics 39, 499\u2013503 (1983).","journal-title":"Biometrics"},{"key":"2478_CR82","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0092-8674(94)90115-5","volume":"76","author":"T Takai","year":"1994","unstructured":"Takai, T., Li, M., Sylvestre, D., Clynes, R. & Ravetch, J. V. FcR \u03b3 chain deletion results in pleiotrophic effector cell defects. Cell 76, 519\u2013529 (1994).","journal-title":"Cell"},{"key":"2478_CR83","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"2478_CR84","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"2478_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/mps1010008","volume":"1","author":"F Ferrara","year":"2018","unstructured":"Ferrara, F. & Temperton, N. Pseudotype neutralization assays: from laboratory bench to data analysis. Methods Protoc. 1, 8 (2018).","journal-title":"Methods Protoc."},{"key":"2478_CR86","doi-asserted-by":"publisher","unstructured":"McInnes, L., Healy, J. & Melville, J. UMAP: uniform manifold approximation and projection for dimension reduction. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1802.03426 (2018).","DOI":"10.48550\/arXiv.1802.03426"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02478-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:03:08Z","timestamp":1780351388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-026-02478-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1038\/s41590-026-02478-7","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.D. and J.N. are cofounders of AstriVax Therapeutics, serve as members of its scientific advisory board and are mentioned as inventors on a patent application related to the discovery and use of YF17D-vectored filovirus vaccines. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}